• LAST PRICE
    4.9000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    4.7700/ 10
  • Ask / Lots
    5.2500/ 7
  • Open / Previous Close
    0.0000 / 4.9000
  • Day Range
    ---
  • 52 Week Range
    Low 1.4300
    High 6.8500
  • Volume
    23
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 5.09
TimeVolumeBDTX
09:32 ET9005.1
09:34 ET226104.95
09:36 ET28684.86
09:38 ET13584.84
09:39 ET72764.8201
09:41 ET96614.74
09:43 ET6054.8
09:45 ET22814.7883
09:48 ET16164.865
09:50 ET3004.9
09:52 ET24674.91
09:54 ET1004.905
09:59 ET11614.89
10:01 ET5004.9
10:03 ET116084.92
10:06 ET5004.9471
10:08 ET1004.93
10:10 ET12004.98
10:12 ET97744.98
10:14 ET5804.99
10:15 ET1004.99
10:17 ET12995
10:19 ET39225
10:21 ET2005
10:24 ET3005
10:26 ET4005
10:28 ET161465
10:30 ET2944.99
10:32 ET2004.99
10:35 ET31005
10:37 ET13014.98
10:44 ET11194.96
10:46 ET4454.97
10:48 ET1004.97
10:50 ET8004.98
10:51 ET12004.98
11:00 ET1004.98
11:04 ET22004.97
11:06 ET1004.98
11:09 ET2854.99
11:13 ET1004.98
11:15 ET51554.99
11:18 ET32324.96
11:20 ET12734.95
11:26 ET39525
11:29 ET2004.995
11:33 ET1005
11:36 ET3004.9961
11:38 ET1004.995
11:40 ET2005
11:45 ET2005
11:49 ET3275
11:51 ET4005
11:54 ET1004.995
11:56 ET28904.99
12:00 ET2854.98
12:05 ET14004.995
12:09 ET3004.995
12:12 ET3004.99
12:14 ET1004.99
12:16 ET1004.99
12:18 ET45315
12:21 ET1005
12:23 ET6004.99
12:27 ET3005
12:30 ET1005
12:32 ET6005
12:34 ET3005
12:36 ET59315
12:38 ET29414.98
12:39 ET1004.98
12:41 ET3244.99
12:52 ET2004.98
12:54 ET51004.98
12:56 ET127085.03
12:57 ET18345.08
12:59 ET3005.1
01:03 ET8215.09
01:10 ET1005.1
01:14 ET65085.14
01:15 ET3005.17
01:19 ET6005.15
01:21 ET13935.13
01:24 ET33195.08
01:26 ET5875.08
01:28 ET1005.08
01:30 ET9005.06
01:32 ET8005.06
01:35 ET4005.045
01:37 ET2735.04
01:39 ET2005.04
01:44 ET2005.04
01:46 ET19085.015
01:50 ET2005.005
01:53 ET1005.005
02:00 ET4695
02:02 ET9254.99
02:11 ET11004.971
02:13 ET21704.99
02:15 ET1004.99
02:18 ET6004.9938
02:20 ET4004.99
02:22 ET11504.97
02:24 ET34004.9723
02:26 ET31004.97
02:29 ET4004.96
02:33 ET76874.95
02:36 ET2004.95
02:49 ET638264.93
02:51 ET34524.94
02:54 ET5324.94
02:56 ET1004.94
02:58 ET20934.94
03:00 ET7904.945
03:02 ET1004.945
03:03 ET7004.95
03:05 ET6004.94
03:07 ET10924.9332
03:09 ET1004.93
03:12 ET119764.9201
03:16 ET4004.93
03:18 ET3004.9377
03:20 ET9594.9
03:21 ET13014.91
03:23 ET8004.92
03:25 ET2004.91
03:27 ET1004.93
03:30 ET25214.905
03:32 ET1004.91
03:36 ET3004.91
03:38 ET5004.91
03:39 ET6004.91
03:41 ET42624.92
03:43 ET1004.93
03:45 ET1004.93
03:48 ET8514.89
03:50 ET2004.88
03:52 ET28924.9
03:54 ET2004.882
03:56 ET20824.91
03:57 ET26254.9
03:59 ET43304.9
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesBDTX
Black Diamond Therapeutics Inc
253.4M
-2.5x
---
United StatesGLSI
Greenwich Lifesciences Inc
257.0M
-28.5x
---
United StatesCRDF
Cardiff Oncology Inc
256.9M
-6.2x
---
United StatesPRLD
Prelude Therapeutics Inc
262.0M
-2.3x
---
United StatesPYXS
Pyxis Oncology Inc
244.2M
-2.2x
---
United StatesELEV
Elevation Oncology Inc
243.7M
-3.3x
---
As of 2024-03-28

Company Information

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The Company is also focused on a development candidate against an undisclosed, validated oncogene.

Contact Information

Headquarters
One Main Street, 14Th FloorCAMBRIDGE, MA, United States 02142
Phone
617-417-5868
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer
Mark Velleca
Executive Vice President - Discovery and Translational Sciences
Elizabeth Buck
Chief Financial Officer, Chief Business Officer
Fang Ni
Chief Operating Officer, General Counsel
Brent Hatzis-Schoch
Chief People Officer
Elizabeth Montgomery

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$253.4M
Revenue (TTM)
$0.00
Shares Outstanding
51.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.64
EPS
$-1.92
Book Value
$2.26
P/E Ratio
-2.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.